Kelcie Waack
Internal Medicine · Southgate, MINPI 1730762246
Payments from drug & device makers
Across 288 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$537
- Shionogi Inc$374
- Novo Nordisk$372
- Otsuka America Pharmaceutical, Inc.$304
- Pfizer$220
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,275100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,275 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 79 | $92,202 |
| ZenpepLipase/Protease/Amylase | 12 | $59,696 |
| JardianceEmpagliflozin | 32 | $35,049 |
| OzempicSemaglutide | 26 | $29,135 |
| FarxigaDapagliflozin Propanediol | 20 | $27,204 |
| TrulicityDulaglutide | 16 | $18,908 |
| EliquisApixaban | 12 | $17,411 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,422 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $12,378 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $10,658 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 361 | $6,050 |
| Naproxen | 14 | $4,740 |
| Novolog FlexpenInsulin Aspart | 18 | $4,630 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 160 | $4,176 |
| Rivastigmine | 25 | $4,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $537 | $111,11195 claims |
| Aimmune Therapeutics, Inc.Zenpep | $177 | $59,69612 claims |
| Boehringer IngelheimJardiance | $147 | $35,04932 claims |
| Novo NordiskOzempic | $372 | $29,13526 claims |
| AstraZenecaFarxiga | $183 | $27,20420 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $157 | $25,08046 claims |
| PfizerEliquis | $220 | $17,41112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Southgate
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.